Key facts
- It has raised $165.4M; the latest was Later Stage VC ($75.0M) in Jan 2026.
- Notable investors include MedTech Innovator, New Enterprise Associates, Keiretsu Forum, KCK Group, WJFS — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Lungpacer
- ·The full record, as it builds
Funding rounds
No funding rounds for Lungpacer are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lungpacer
Manufacturer of therapy devices intended for the treatment of the diaphragm muscle in critically ill patients who require mechanical ventilation. The company's diaphragm therapy system uses the body's nervous system to send messages to the diaphragm muscle to the source of natural breathing and provides repetitive exercises to rebuild diaphragm muscle strength critical to healthy breathing, enabling patients to prevent and reverse muscle-disuse atrophy and maintain diaphragmatic endurance.
- Sector
- Healthcare
- HQ
- Exton, PA, United States
- Founded
- 2009
- Employees
- 55
- Website
- lungpacer.com/
- Ownership
- Privately Held (backing)
Lungpacer doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lungpacer shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lungpacer in its N-PORT filings yet. We sweep new filings monthly.